Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression.
González-Martínez I, Cerro-Herreros E, Moreno N, García-Rey A, Espinosa-Espinosa J, Carrascosa-Sàez M, Piqueras-Losilla D, Arzumanov A, Seoane-Miraz D, Jad Y, Raz R, Wood MJ, Varela MA, Llamusí B, Artero R. González-Martínez I, et al. Mol Ther Nucleic Acids. 2023 Sep 5;34:102024. doi: 10.1016/j.omtn.2023.09.001. eCollection 2023 Dec 12. Mol Ther Nucleic Acids. 2023. PMID: 37744174 Free PMC article.
BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice.
Overby SJ, Cerro-Herreros E, Espinosa-Espinosa J, González-Martínez I, Moreno N, Fernández-Costa JM, Balaguer-Trias J, Ramón-Azcón J, Pérez-Alonso M, Møller T, Llamusí B, Artero R. Overby SJ, et al. Among authors: gonzalez martinez i. Pharmaceutics. 2023 Mar 31;15(4):1118. doi: 10.3390/pharmaceutics15041118. Pharmaceutics. 2023. PMID: 37111604 Free PMC article.
Serum GDF-15 Levels Accurately Differentiate Patients with Primary Mitochondrial Myopathy, Manifesting with Exercise Intolerance and Fatigue, from Patients with Chronic Fatigue Syndrome.
Bermejo-Guerrero L, de Fuenmayor-Fernández de la Hoz CP, Guerrero-Molina MP, Martín-Jiménez P, Blázquez A, Serrano-Lorenzo P, Lora D, Morales-Conejo M, González-Martínez I, López-Jiménez EA, Martín MA, Domínguez-González C. Bermejo-Guerrero L, et al. Among authors: gonzalez martinez i. J Clin Med. 2023 Mar 22;12(6):2435. doi: 10.3390/jcm12062435. J Clin Med. 2023. PMID: 36983435 Free PMC article.
Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy.
Cerro-Herreros E, González-Martínez I, Moreno-Cervera N, Overby S, Pérez-Alonso M, Llamusí B, Artero R. Cerro-Herreros E, et al. Among authors: gonzalez martinez i. Mol Ther Nucleic Acids. 2020 Sep 4;21:837-849. doi: 10.1016/j.omtn.2020.07.021. Epub 2020 Jul 21. Mol Ther Nucleic Acids. 2020. PMID: 32805487 Free PMC article.
Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model.
Overby SJ, Cerro-Herreros E, González-Martínez I, Varela MA, Seoane-Miraz D, Jad Y, Raz R, Møller T, Pérez-Alonso M, Wood MJ, Llamusí B, Artero R. Overby SJ, et al. Among authors: gonzalez martinez i. Mol Ther Nucleic Acids. 2022 Feb 10;27:1146-1155. doi: 10.1016/j.omtn.2022.02.003. eCollection 2022 Mar 8. Mol Ther Nucleic Acids. 2022. PMID: 35282418 Free PMC article.
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy.
Cerro-Herreros E, González-Martínez I, Moreno N, Espinosa-Espinosa J, Fernández-Costa JM, Colom-Rodrigo A, Overby SJ, Seoane-Miraz D, Poyatos-García J, Vilchez JJ, López de Munain A, Varela MA, Wood MJ, Pérez-Alonso M, Llamusí B, Artero R. Cerro-Herreros E, et al. Among authors: gonzalez martinez i. Mol Ther Nucleic Acids. 2021 Jul 29;26:174-191. doi: 10.1016/j.omtn.2021.07.017. eCollection 2021 Dec 3. Mol Ther Nucleic Acids. 2021. PMID: 34513303 Free PMC article.